William R. Hiatt, MD


President, CPC

Professor of Medicine and Cardiology, University of Colorado School of Medicine

William R. Hiatt, MD, has masterfully led CPC as President since 1996. Dr. Hiatt’s extensive involvement in leading international Steering Committees and global clinical trial initiatives provides an unparalleled perspective on clinical trial development. He is a past Chair of the United States Food and Drug Administration (FDA) Cardiovascular and Renal Advisory Committee (2003-08), served several years on the Endocrinologic and Metabolic Drugs Advisory Committee and currently serves as a consultant to the FDA.

His research at the CPC has pioneered new methods to control endpoint variability in clinical trials. Dr. Hiatt has over 230 peer-reviewed publications. His current trial focus is in developing new therapeutics for peripheral artery disease addressing both limb symptoms and cardiovascular risk.

Active in many national societies, Dr. Hiatt is a past-president of the Society for Vascular Medicine, is a fellow in the American Heart Association (AHA) and the American College of Physicians and a past chair of the AHA Peripheral Vascular Disease Council. He is also the co-editor of the TASC international guidelines for peripheral artery disease.

Dr. Hiatt serves on the editorial board as an associate editor for the Journal of Vascular Medicine, the Cochrane Review Group and is guest editor for Circulation and section editor for the Journal of the American College of Cardiology.

In 2014 he was recognized as a Distinguished Scientist of the American Heart Association. He has received two outstanding medical student teacher awards and has been elected several times Best Doctors in America (most recently in 2012). In 2008 he received the Robert W. Schrier Award of Excellence from the Department of Medicine, University of Colorado and he received the Julius H. Jacobson II, MD Physician Excellence Award from the Vascular Disease Foundation.

Research activities include studies evaluating the pathophysiology and epidemiology of peripheral artery disease, mechanisms of supervised exercise as an effective treatment modality for claudication, and numerous clinical trials to develop new therapies for claudication and critical leg ischemia.


Ticagrelor versus Clopidogrel in
Symptomatic Peripheral Artery Disease.

William R. Hiatt, M.D., F. Gerry R. Fowkes, M.D., Gretchen Heizer, M.S.,
Jeffrey S. Berger, M.D., Iris Baumgartner, M.D., Peter Held, M.D., Ph.D.,
Brian G. Katona, Pharm.D., Kenneth W. Mahaffey, M.D., Lars Norgren, M.D., Ph.D.,
W. Schuyler Jones, M.D., Juuso Blomster, M.D., Marcus Millegård, M.Sc.,
Craig Reist, Ph.D., and Manesh R. Patel, M.D.,
for the EUCLID Trial Steering Committee and Investigators.

Prioritisation of treatments for lower extremity peripheral artery disease in low- and middle-income countries.

Fowkes FG, Forster R, Levin CE, Naidoo NG, Roy A, Shu C, Spertus J, Fang K, Bechara-Zamudio L, Catalano M, Visona A, Nikol S, Fletcher JP, Jaff MR, Hiatt WR, Norgren L; (TASC) on behalf of the Inter-Society Consensus for the Management of Peripheral Arterial Disease.

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.

Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial.

Berger JS, Katona BG, Jones WS, Patel MR, Norgren L, Baumgartner I, Blomster J, Mahaffey KW, Held P, Millegård M, Heizer G, Reist C, Fowkes FG10, Hiatt WR.

Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study.

Violi F, Davì G, Proietti M, Pastori D, Hiatt WR, Corazza GR, Perticone F, Pignatelli P, Farcomeni A, Vestri AR, Lip GY, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators.

Urinary 11-dehydro-Thromboxane B2 is associated with cardiovascular events and mortality in atrial fibrillation patients.

Pastori D, Pignatelli P, Farcomeni A, Cangemi R, Hiatt WR, Bartimoccia S, Nocella C, Vicario T, Bucci T, Carnevale R, Lip GY, Violi F.

For additional research publications please visit: https://www.researchgate.net/researcher/39301333_William_R_Hiatt